title: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides.
abstract: Mycosis fungoides is a T-cell lymphoma that arises in the skin and progresses at highly variable rates. Nonradomized studies have suggested that early aggressive therapy may improve the prognosis in this usually fatal disease. We studied 103 patients with mycosis fungoides, who, after complete staging, were randomly assigned to receive either combination therapy, consisting of 3000 cGy of electron-beam radiation to the skin combined with parenteral chemotherapy with cyclophosphamide, doxorubicin, etoposide, and vincristine (n = 52) or sequential topical treatment (n = 51). The prognostic factors were well balanced in the two groups. Combined therapy produced considerable toxicity: 12 patients required hospitalization for fever and transient neutropenia, 5 had congestive heart failure, and 2 were later found to have acute nonlymphocytic leukemia. Patients receiving combined therapy had a significantly higher rate of complete response, documented by biopsy, than patients receiving conservative therapy (38 percent vs. 18 percent; P = 0.032). After a median follow-up of 75 months, however, there was no significant difference between the treatment groups in disease-free or overall survival. We conclude that early aggressive therapy with radiation and chemotherapy does not improve the prognosis for patients with mycosis fungoides as compared with conservative treatment beginning with sequential topical therapies.
authors.affiliation: National Cancer Institute-Navy Medical Oncology Branch, Bethesda, Md 20814.
authors.forename: F J
authors.initials: FJ
authors.lastname: Kaye
authors.forename: P A
authors.initials: PA
authors.lastname: Bunn
authors.forename: S M
authors.initials: SM
authors.lastname: Steinberg
authors.forename: J L
authors.initials: JL
authors.lastname: Stocker
authors.forename: D C
authors.initials: DC
authors.lastname: Ihde
authors.forename: A B
authors.initials: AB
authors.lastname: Fischmann
authors.forename: E J
authors.initials: EJ
authors.lastname: Glatstein
authors.forename: G P
authors.initials: GP
authors.lastname: Schechter
authors.forename: R M
authors.initials: RM
authors.lastname: Phelps
authors.forename: F M
authors.initials: FM
authors.lastname: Foss
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004583:Electrons; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D011897:Random Allocation; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide